You are viewing the site in preview mode

Skip to main content

Table 2 Objective response rate by RECIST 1.1 assessment for 55 patients

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Type of response N (%)
Complete response 0
Partial response 14 (25%)
Stable disease 28 (51%)
Progressive disease 10 (18%)
Non-evaluable 3 (5%)
  1. RECIST Response Evaluation Criteria In Solid Tumors
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us